"This agreement illustrates our growing momentum in international cord blood markets, including the recent approvals for the AXP in Thailand and BioArchive in China," said Matthew Plavan, Chief Executive Officer of ThermoGenesis. "We are pleased to expand our partnership with Concessus, a proven leader in quality healthcare product distribution for Western Europe," he added.

About Concessus, S.A.

Concessus, S.A. has more than 20 years history in the blood banking field. The qualifications of our team and the continuous high quality support we provide our customers distinguishes Concessus from others who are acting in the same field of activity. We sell our equipment across Western Europe for a large variety of customers, blood banks, research institutes, universities and hospitals. Concessus is focused on providing quality solutions to the customers, that's why our policy is based on two goals – continuous improvement and customer care service.

About ThermoGenesis Corp.

ThermoGenesis Corp. ( www.thermogenesis.com ) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These include:
  • The BioArchive ® System, an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries for cryopreserving and archiving cord blood stem cell units for transplant.
  • AXP ® AutoXpress ® Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP ® MarrowXpress ® and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. The MXP is used for the preparation of cell concentrates, including stem cells from bone marrow aspirates in the laboratory setting.
  • The Res-Q ® 60 BMC/PRP (Res-Q), a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates and whole blood for platelet rich plasma (PRP).

The ThermoGenesis Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=14120

This press release contains forward-looking statements. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors including timing of FDA and foreign regulatory approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal years 2012 and 2013, and introduction of competitive products and other factors beyond our control could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2012 and 2013. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
CONTACT: Web site: http://www.thermogenesis.com         Contact: Investor Relations         +1-916-858-5107, or         Email: ir@thermogenesis.com

ThermoGenesis Corp. Logo

If you liked this article you might like

Biotech Movers: Cesca Up Strong After Securing CAR-T Cell Patent

Cesca Therapeutics (KOOL) Highlighted As Weak On High Volume

Heavy Volume And Pre-Market Movement For Cesca Therapeutics (KOOL)

7 Stocks Under $10 Making Big Moves

Weak On High Volume: Cesca Therapeutics (KOOL)